Skip to content
RDL Network logo
798P NeoTrio – Optimal neoadjuvant (NAT) sequencing of anti-PD-1 and BRAF targeted therapy (TT) in BRAF mutant stage III melanoma: Results of histopathological analysis — Jorja Braden (2022) | RDL Network